Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Results Physiotherapy opens new clinic in Collierville

Collierville now has a new choice for treating Orthopedic problems, sports injuries and a variety of conditions that cause pain. Results Physiotherapy has opened a new physical therapy clinic in Collierville, and it is the fifth location in the greater Memphis area.

4 Mar 2011

Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA

Protalex, Inc, a clinical stage biopharmaceutical company which is engaged in developing a class of drugs for treating autoimmune and inflammatory diseases, today announced enrollment of the first patients in the 3rd cohort of its ongoing multicenter Phase 1b dose escalation clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA) being conducted in South Africa. The dose was increased by a factor of two from the 2nd cohort.

3 Mar 2011

Early diagnosis of juvenile idiopathic arthritis critical to avoid disability, deformity

While lab tests and imaging can sometimes help diagnose juvenile idiopathic arthritis (JIA), a physical examination and thorough patient history are the most valuable tools in identifying this disease. According to a new literature review from the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), the rate of false positives in laboratory evaluations and imaging studies meant to screen for juvenile arthritis makes their value limited.

3 Mar 2011

FADD protein discovery can lead to better cancer and autoimmune disease drugs

Reporting in Nature, scientists from Thomas Jefferson University have determined that a single protein called FADD controls multiple cell death pathways, a discovery that could lead to better, more targeted autoimmune disease and cancer drugs.

3 Mar 2011

Turmeric may be 'the right spice' to fight colon cancer

Turmeric, a bright yellow spice from south Asia belonging to the ginger family, is the main ingredient in curries - and ancient wisdom suggests that it's also good for your health. Taking this wisdom to the laboratory, Tel Aviv University researchers have discovered that turmeric's active ingredient called curcumin amplifies the therapeutic activity of highly toxic anti-inflammatory drugs used to fight colon cancer when used at high doses.

3 Mar 2011

Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack

Osiris Therapeutics, Inc., today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal, an adult mesenchymal stem cell therapy, in patients experiencing their first heart attack.

3 Mar 2011

New PSA campaign to raise awareness about autoimmune diseases

The American Autoimmune Related Diseases Association Inc. has unveiled a multi-media public service/awareness campaign titled "We are 50 Million" to herald March 2011 as National Autoimmune Diseases Awareness Month.

2 Mar 2011

'Prehabilitation' exercise program can improve strength, functional ability before knee replacement surgery

A comprehensive "prehabilitation" exercise program for patients with severe knee arthritis can improve strength and functional ability before knee replacement surgery, reports a study in the February issue of The Journal of Strength and Conditioning Research, official research journal of the National Strength and Conditioning Association.

2 Mar 2011

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

1 Mar 2011

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Plexxikon Inc. today announced it has entered into a merger agreement with Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company.

28 Feb 2011

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.

28 Feb 2011

Exactech fourth quarter total revenue increases 7% to $51.8 million

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, extremities, spine and biologic materials, announced today that revenue for 2010 increased 7% to $190.5 million from $177.3 million in 2009. Diluted earnings per share for the year was $0.80 based on net income of $10.5 million.

28 Feb 2011

SQI Diagnostics first quarter net loss increases to $2,255,000

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced its financial and operational results for the first quarter ended December 31, 2010.

28 Feb 2011

New horse stem cell discovery aids in preclinical model development for human degenerative diseases

In a world first, pluripotent stem cells have been generated from horses by a team of researchers led by Dr. Andras Nagy at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital and Dr. Lawrence Smith at the University of Montreal's Faculty of Veterinary Science.

28 Feb 2011

New research may shed light on how HIV virus reactivates from latency

New research enhances the current knowledge of how human immunodeficiency virus type-1, which causes AIDS, controls the cell cycle of cells that it infects. The new findings may shed light on how the virus reactivates after entering a dormant state, called latency.

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Pharming, Santarus receive FDA refusal to file letter for RHUCIN BLA

Specialty biopharmaceutical company Santarus, Inc.and biotech company Pharming Group NV today announced the receipt of a "refusal to file" letter from the U.S. Food and Drug Administration for the RHUCIN Biologics License Application submitted by Pharming.

28 Feb 2011

Takeda receives FDA approval for EDARBI to treat hypertension in adults

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration approved EDARBI for the treatment of hypertension, or high blood pressure, in adults.

27 Feb 2011

ICTS concludes enrollment months ahead of schedule for rheumatology study

ICTS, the patient recruitment and clinical trial services company, has successfully completed the fifth in a series of rheumatology study recruitment efforts for the same sponsor. Using an integrated approach that centered around a study website, social media, geographically initiated keyword search advertising, and also included site enrollment toolkits, the program exceeded the enrollment timelines established by the sponsor.

25 Feb 2011

Savient launches KRYSTEXXA in the U.S.

Savient Pharmaceuticals, Inc. announced the official full U.S. commercial launch of KRYSTEXXA™ (pegloticase), which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic gout in adult patients refractory to conventional therapy. KRYSTEXXA is now the first and only therapy available to address this unmet medical need.

25 Feb 2011

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Results Physiotherapy opens new clinic in Collierville

Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA

Early diagnosis of juvenile idiopathic arthritis critical to avoid disability, deformity

FADD protein discovery can lead to better cancer and autoimmune disease drugs

Turmeric may be 'the right spice' to fight colon cancer

Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack

New PSA campaign to raise awareness about autoimmune diseases

'Prehabilitation' exercise program can improve strength, functional ability before knee replacement surgery

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Exactech fourth quarter total revenue increases 7% to $51.8 million

SQI Diagnostics first quarter net loss increases to $2,255,000

New horse stem cell discovery aids in preclinical model development for human degenerative diseases

New research may shed light on how HIV virus reactivates from latency

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Pharming, Santarus receive FDA refusal to file letter for RHUCIN BLA

Takeda receives FDA approval for EDARBI to treat hypertension in adults

ICTS concludes enrollment months ahead of schedule for rheumatology study

Savient launches KRYSTEXXA in the U.S.

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in